Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases Portfolio News / By Karina Tin February 29, 2024 Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases Read More »
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP Portfolio News / By Karina Tin February 26, 2024 NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP Read More »
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications Portfolio News / By Karina Tin February 26, 2024 Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications Read More »
Synthekine Appoints Geoff Nosrati, Ph.D., as Chief Business Officer and Announces Executive Leadership Changes Portfolio News / By Karina Tin February 21, 2024 Synthekine Appoints Geoff Nosrati, Ph.D., as Chief Business Officer and Announces Executive Leadership Changes Read More »
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon Portfolio News / By Karina Tin February 20, 2024 RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon Read More »
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin February 15, 2024 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update Read More »
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders Portfolio News / By Karina Tin February 8, 2024 Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders Read More »
Tenaya Therapeutics Announces Pricing of Underwritten Offering Portfolio News / By Karina Tin February 8, 2024 Tenaya Therapeutics Announces Pricing of Underwritten Offering Read More »
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader Portfolio News / By Karina Tin February 1, 2024 Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader Read More »
Remix Therapeutics™ Appoints Dominic Reynolds, Ph.D., as Chief Scientific Officer Portfolio News / By Karina Tin February 1, 2024 Remix Therapeutics™ Appoints Dominic Reynolds, Ph.D., as Chief Scientific Officer Read More »
